Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

SRPT

Live52w low +69.9%

Annual Quarterly

Core line items from SRPT's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Annual Quarterly

Entity: SAREPTA THERAPEUTICS, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-04	Q1 2026 2026-03-31	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30
Revenue	$384.41M	$330.51M	$1.86B	$1.49B	$1.12B
Operating Income	Not available	$358.43M	$-699.78M	$-288.20M	$-184.81M
Net Income	Not available	$330.96M	$-713.41M	$-50.57M	$196.89M
EPS (Diluted)	$0.29	$2.88	$-7.13	$-0.50	$1.89
Total Assets	Not available	$3.18B	$3.35B	$3.49B	$3.68B
Total Liabilities	Not available	$1.67B	$2.21B	$2.17B	$2.32B
Cash & Equivalents	Not available	$464.45M	$801.28M	$613.08M	$510.60M
Free Cash Flow OCF − CapEx	Not available	$-204.76M	$-307.45M	$-435.07M	$-397.55M
Shares Outstanding	Not available	105.57M	104.96M	104.77M	97.71M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from SRPT's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w low +69.9%

Entity: SAREPTA THERAPEUTICS, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-04	Q1 2026 2026-03-31	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30
Revenue	$384.41M	$330.51M	$1.86B	$1.49B	$1.12B
Operating Income	Not available	$358.43M	$-699.78M	$-288.20M	$-184.81M
Net Income	Not available	$330.96M	$-713.41M	$-50.57M	$196.89M
EPS (Diluted)	$0.29	$2.88	$-7.13	$-0.50	$1.89
Total Assets	Not available	$3.18B	$3.35B	$3.49B	$3.68B
Total Liabilities	Not available	$1.67B	$2.21B	$2.17B	$2.32B
Cash & Equivalents	Not available	$464.45M	$801.28M	$613.08M	$510.60M
Free Cash Flow OCF − CapEx	Not available	$-204.76M	$-307.45M	$-435.07M	$-397.55M
Shares Outstanding	Not available	105.57M	104.96M	104.77M	97.71M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.